Free Trial

West Pharmaceutical Services (WST) Stock Price, News & Analysis

$297.24
-3.06 (-1.02%)
(As of 09/6/2024 ET)
Today's Range
$294.51
â–Ľ
$303.53
50-Day Range
$277.16
â–Ľ
$333.25
52-Week Range
$265.00
â–Ľ
$413.70
Volume
293,091 shs
Average Volume
554,205 shs
Market Capitalization
$21.65 billion
P/E Ratio
39.21
Dividend Yield
0.27%
Price Target
$442.75

West Pharmaceutical Services MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
49.0% Upside
$442.75 Price Target
Short Interest
Healthy
1.75% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.53
Upright™ Environmental Score
News Sentiment
1.45mentions of West Pharmaceutical Services in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$904,104 Sold Last Quarter
Proj. Earnings Growth
17.55%
From $6.44 to $7.57 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.94 out of 5 stars

Medical Sector

8th out of 910 stocks

Surgical & Medical Instruments Industry

2nd out of 95 stocks

WST stock logo

About West Pharmaceutical Services Stock (NYSE:WST)

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

WST Stock Price History

WST Stock News Headlines

West to Participate in Upcoming Investor Conference
The solution to fast food’s wage hike crisis
Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.
The solution to fast food’s wage hike crisis
Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.
See More Headlines
Receive WST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/25/2024
Ex-Dividend for 8/7 Dividend
7/31/2024
Dividend Payable
8/07/2024
Today
9/07/2024
Next Earnings (Estimated)
10/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
CUSIP
95530610
Employees
10,600
Year Founded
1923

Price Target and Rating

Average Stock Price Target
$442.75
High Stock Price Target
$536.00
Low Stock Price Target
$375.00
Potential Upside/Downside
+49.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$593.40 million
Pretax Margin
21.25%

Debt

Sales & Book Value

Annual Sales
$2.88 billion
Cash Flow
$9.93 per share
Book Value
$35.52 per share

Miscellaneous

Free Float
72,457,000
Market Cap
$21.65 billion
Optionable
Optionable
Beta
1.01

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

  • West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products globally, providing a diverse revenue stream.
  • The company operates in two segments, Proprietary Products and Contract-Manufactured, which allows for flexibility and adaptability in changing market conditions.
  • Recent developments in the healthcare industry have increased the demand for innovative drug delivery systems, positioning West Pharmaceutical Services, Inc. for potential growth.
  • With a focus on quality and safety, West Pharmaceutical Services, Inc. has established a strong reputation in the industry, attracting potential investors.
  • The current stock price of West Pharmaceutical Services, Inc. is stable and has shown positive growth trends in recent periods, indicating potential value for investors.

Cons

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

  • While the company has a strong reputation, competition in the healthcare industry is fierce, leading to potential challenges in maintaining market share and profitability.
  • Global economic uncertainties and regulatory changes could impact the demand for healthcare products and services, affecting West Pharmaceutical Services, Inc.'s financial performance.
  • Investing in healthcare-related companies carries inherent risks due to factors such as regulatory approvals, market volatility, and potential litigation issues.
  • Fluctuations in raw material prices and supply chain disruptions could impact the production costs and margins of West Pharmaceutical Services, Inc., affecting its profitability.
  • While the company has shown positive growth trends, past performance is not indicative of future results, and investors should carefully assess the risks before making investment decisions.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 19, 2024. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

WST Stock Analysis - Frequently Asked Questions

How have WST shares performed this year?

West Pharmaceutical Services' stock was trading at $352.12 at the beginning of the year. Since then, WST stock has decreased by 15.6% and is now trading at $297.24.
View the best growth stocks for 2024 here
.

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services, Inc. (NYSE:WST) posted its quarterly earnings results on Thursday, July, 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.74 by $0.22. West Pharmaceutical Services's quarterly revenue was down 6.9% compared to the same quarter last year.
Read the conference call transcript
.

What is Eric M. Green's approval rating as West Pharmaceutical Services' CEO?

107 employees have rated West Pharmaceutical Services Chief Executive Officer Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among the company's employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Does West Pharmaceutical Services have any subsidiaries?

West Pharmaceutical Services subsidiaries include these companies: Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., The Tech Group Inc., Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), TGPR Holdings Limited, WD SG Pte. Ltd., and others.

Who are West Pharmaceutical Services' major shareholders?

Top institutional shareholders of West Pharmaceutical Services include Bank of New York Mellon Corp (4.49%), APG Asset Management N.V. (3.20%), Massachusetts Financial Services Co. MA (0.87%) and Kayne Anderson Rudnick Investment Management LLC (0.82%). Insiders that own company stock include Eric Mark Green, Thomas W Hofmann, Quintin J Lai, Annette F Favorite, Bernard Birkett, Cindy Reiss-Clark, Silji Abraham, Charles Witherspoon and Chad Winters.
View institutional ownership trends
.

How do I buy shares of West Pharmaceutical Services?

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of West Pharmaceutical Services own?

Based on aggregate information from My MarketBeat watchlists, some other companies that West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V) and Alibaba Group (BABA).

This page (NYSE:WST) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners